| 000 | 01601 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250517233135.0 | ||
| 264 | 0 | _c20181213 | |
| 008 | 201812s 0 0 eng d | ||
| 022 | _a1950-6007 | ||
| 024 | 7 |
_a10.1016/j.biopha.2018.07.078 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCzyrski, Andrzej | |
| 245 | 0 | 0 |
_aDetermination of gliclazide minimum concentration in type 2 diabetes mellitus patients. _h[electronic resource] |
| 260 |
_bBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie _cOct 2018 |
||
| 300 |
_a1267-1270 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 |
_aBlood Glucose _xdrug effects |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
| 650 | 0 | 4 | _aDrug Dosage Calculations |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 |
_aFasting _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGliclazide _xadministration & dosage |
| 650 | 0 | 4 | _aGlycated Hemoglobin |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aInsulin _xblood |
| 650 | 0 | 4 | _aLinear Models |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMedication Adherence |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 | _aTablets |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aResztak, Matylda | |
| 700 | 1 | _aHermann, Tadeusz | |
| 773 | 0 |
_tBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie _gvol. 106 _gp. 1267-1270 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.biopha.2018.07.078 _zAvailable from publisher's website |
| 999 |
_c28741212 _d28741212 |
||